These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34365124)

  • 1. Online surveillance of novel psychoactive substances (NPS): Monitoring Reddit discussions as a predictor of increased NPS-related exposures.
    Barenholtz E; Krotulski AJ; Morris P; Fitzgerald ND; Le A; Papsun DM; Logan BK; Hahn WE; Goldberger BA; Cottler LB; Palamar JJ
    Int J Drug Policy; 2021 Dec; 98():103393. PubMed ID: 34365124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
    Napoletano S; Basile G; Lo Faro AF; Negro F
    Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of new psychoactive substances in Australian wastewater utilising direct injection liquid chromatography coupled to tandem mass spectrometry.
    Bade R; Eaglesham G; Shimko KM; Mueller J
    Talanta; 2023 Jan; 251():123767. PubMed ID: 35973252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brorphine-Investigation and quantitation of a new potent synthetic opioid in forensic toxicology casework using liquid chromatography-mass spectrometry.
    Krotulski AJ; Papsun DM; Noble C; Kacinko SL; Logan BK
    J Forensic Sci; 2021 Mar; 66(2):664-676. PubMed ID: 33201526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical symptoms and blood concentration of new psychoactive substances (NPS) in intoxicated and hospitalized patients in the Budapest region of Hungary (2018-19).
    Institóris L; Kovács K; Sija É; Berkecz R; Körmöczi T; Németh I; Elek I; Bakos Á; Urbán I; Pap C; Kereszty É
    Clin Toxicol (Phila); 2022 Jan; 60(1):18-24. PubMed ID: 34080493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring new psychoactive substances: Exploring the contribution of an online discussion forum.
    Rhumorbarbe D; Morelato M; Staehli L; Roux C; Jaquet-Chiffelle DO; Rossy Q; Esseiva P
    Int J Drug Policy; 2019 Nov; 73():273-280. PubMed ID: 30967328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective identification of new psychoactive substances in patient samples submitted for clinical drug analysis.
    Axelsson MAB; Lövgren H; Kronstrand R; Green H; Bergström MA
    Basic Clin Pharmacol Toxicol; 2022 Nov; 131(5):420-434. PubMed ID: 36028947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and time course of benzodiazepine-type new psychoactive substance detections in Australia: results from the Emerging Drugs Network of Australia - Victoria project 2020-2022.
    Syrjanen R; Greene SL; Weber C; Smith JL; Hodgson SE; Abouchedid R; Gerostamoulos D; Maplesden J; Knott J; Hollerer H; Rotella JA; Graudins A; Schumann JL;
    Int J Drug Policy; 2023 Dec; 122():104245. PubMed ID: 37944339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project.
    Helander A; Bäckberg M; Beck O
    PLoS One; 2020; 15(4):e0232038. PubMed ID: 32324788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytically confirmed illicit and novel psychoactive drug use in Western Australian emergency departments: initial results from the Emerging Drugs Network of Australia (EDNA).
    Weber C; Smith JL; Soderstrom J; Burrows S; McCutcheon D; Oosthuizen F; Fatovich DM;
    Clin Toxicol (Phila); 2023 Jul; 61(7):500-508. PubMed ID: 37449677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New psychoactive substances: An actual problem or an overestimated phenomenon?
    Vaiano F; Pascali JP; Bertol E
    Forensic Sci Int; 2019 Nov; 304():109941. PubMed ID: 31574421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No prescription? No problem: A qualitative study investigating self-medication with novel psychoactive substances (NPS).
    Holborn T; Schifano F; Deluca P
    Int J Drug Policy; 2023 Aug; 118():104109. PubMed ID: 37422986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New/emerging psychoactive substances and associated psychopathological consequences.
    Schifano F; Napoletano F; Chiappini S; Guirguis A; Corkery JM; Bonaccorso S; Ricciardi A; Scherbaum N; Vento A
    Psychol Med; 2021 Jan; 51(1):30-42. PubMed ID: 31327332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Synthetic Cannabinoid Metabolites in Human Blood in the Absence of Parent Compounds: A Stability Assessment.
    Krotulski AJ; Bishop-Freeman SC; Mohr ALA; Logan BK
    J Anal Toxicol; 2021 Feb; 45(1):60-68. PubMed ID: 32435808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014.
    Neicun J; Yang JC; Shih H; Nadella P; van Kessel R; Negri A; Czabanowska K; Brayne C; Roman-Urrestarazu A
    PLoS One; 2020; 15(10):e0241056. PubMed ID: 33125395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global strategy for New Psychoactive Substances: an update.
    Vicknasingam B; Narayanan S; Singh D; Corazza O
    Curr Opin Psychiatry; 2020 Jul; 33(4):295-300. PubMed ID: 32398543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
    Gray R; Bressington D; Hughes E; Ivanecka A
    J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring the use of novel psychoactive substances in Australia by wastewater-based epidemiology.
    Jaunay EL; Bade R; Paxton KR; Nadarajan D; Barry DC; Zhai Y; Tscharke BJ; O'Brien JW; Mueller J; White JM; Simpson BS; Gerber C
    Sci Total Environ; 2024 Apr; 919():170473. PubMed ID: 38286292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public health surveillance of new psychoactive substances: recent developments.
    Fitzgerald ND; Cottler LB; Palamar JJ
    Curr Opin Psychiatry; 2024 Jul; 37(4):270-276. PubMed ID: 38587019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances.
    Deligianni E; Daniel OJ; Corkery JM; Schifano F; Lione LA
    Br J Clin Pharmacol; 2020 Mar; 86(3):505-516. PubMed ID: 31495968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.